MedTrace Logo

Disease Management for Smoking Cessation

NCT00440115 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2017-06-07

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to assess the effectiveness of both high and low intensity, disease management programs for smoking. The hypotheses are to compare abstinence from cigarettes, the number of quit attempts, and smokers motivation at 24 months between participants receiving high and low intensity disease management and those receiving usual care.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

High intensity disease management

Health education mailings, 6 motivation interviews/counseling

BEHAVIORAL

Low intensity disease management

Health education mailings, one motivation interview/counseling

BEHAVIORAL

Comparison group

Health education mailings

DRUG

Bupropion

Buproprion or Nicotine Replacement Therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Edward F. Ellerbeck, MD, MPH · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-12-31
Completion
2010-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440115 on ClinicalTrials.gov